Document is current

Article History

Received: 18 July 2018

Accepted: 12 February 2019

First Online: 5 March 2019

Authors’ information

: Correspondence should be addressed to Matthieu Legrand.

: Included in the manuscript.

: Not applicable.

: ML reports consulting fees from Novartis, lecture fees from Baxter and Freseniu, Research support from Shingotec. EF received consulting fees from Edwards Lifesciences, consulting fees from Drager, consulting fees from General Electric Healthcare, lecture fees from Fresenius Kabi, and lecture fees from Baxter. MLeone declares COIs with Amomed (consulting, lecture), Aguettant (consulting), MSD (consulting, lecture), Pfizer (lecture), Aspen (lecture), Orion (lecture), Octapharma (lecture). PR is a co-founder of CardioRenal and declares personal fees (consulting) from Novartis, NovoNordisk, Relypsa, AstraZeneca, Grünenthal, Idorsia, Stealth Peptides, Fresenius, Vifor Fresenius Medical Care Renal Pharma, Vifor, and Clinical Trials Mobile Application; and lecture fees from Bayer and CVRx. AM reports personal fees from Novartis, Orion, Roche, Servier, Cardiorentis, Adrenomed, ZSPharma, Abbott, Neuro Tronik, Sphingotec, research grants from Critical diagnostics, MyCartis and Adrenomed; BD, EV, PC, and BP declare no conflict of interest. EG declares consultant fees from Magnisense and Adrenomed and research fees from Retia Medical, Deltex Medical, and Sphingotec.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.